MX2019010367A - Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1). - Google Patents

Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).

Info

Publication number
MX2019010367A
MX2019010367A MX2019010367A MX2019010367A MX2019010367A MX 2019010367 A MX2019010367 A MX 2019010367A MX 2019010367 A MX2019010367 A MX 2019010367A MX 2019010367 A MX2019010367 A MX 2019010367A MX 2019010367 A MX2019010367 A MX 2019010367A
Authority
MX
Mexico
Prior art keywords
antibody formulation
aqueous anti
antibody
formulation
relates
Prior art date
Application number
MX2019010367A
Other languages
English (en)
Inventor
Del Rio Alessandra
Rinaldi Gianluca
FRATARCANGELI Silvia
James Shopik Michael
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2019010367A publication Critical patent/MX2019010367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una formulación novedosa de anticuerpo anti-PD-L1. En particular, la invención se refiere a una formulación farmacéutica acuosa del anticuerpo anti-PD-L1 Avelumab.
MX2019010367A 2017-03-06 2018-03-06 Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1). MX2019010367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17159354 2017-03-06
PCT/EP2018/055404 WO2018162446A1 (en) 2017-03-06 2018-03-06 Aqueous anti-pd-l1 antibody formulation

Publications (1)

Publication Number Publication Date
MX2019010367A true MX2019010367A (es) 2019-12-02

Family

ID=58264417

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010367A MX2019010367A (es) 2017-03-06 2018-03-06 Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).

Country Status (15)

Country Link
US (1) US20200016267A1 (es)
EP (1) EP3592382A1 (es)
JP (1) JP7379159B2 (es)
KR (1) KR20190125363A (es)
CN (1) CN110392578B (es)
AR (1) AR111229A1 (es)
AU (1) AU2018229724A1 (es)
BR (1) BR112019018401A2 (es)
CA (1) CA3055402A1 (es)
EA (1) EA201992027A1 (es)
IL (1) IL268943B2 (es)
MX (1) MX2019010367A (es)
SG (1) SG11201908091QA (es)
TW (1) TW201834639A (es)
WO (1) WO2018162446A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20181400A1 (es) 2015-12-07 2018-09-07 Merck Patent Gmbh Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
US20210361680A1 (en) * 2018-05-03 2021-11-25 Normoxys, Inc. Inositol-based immunotherapies
WO2020108497A1 (zh) * 2018-11-29 2020-06-04 和铂医药（香港）有限公司 一种抗pd-l1抗体制剂
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1314437T3 (da) * 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
ES2553987T3 (es) * 2003-12-25 2015-12-15 Kyowa Hakko Kirin Co., Ltd. Preparación farmacéutica de base acuosa estable que contiene anticuerpo
KR20190116563A (ko) * 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN103987405B (zh) * 2011-11-28 2017-03-29 默克专利股份公司 抗pd‑l1抗体及其用途
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2014045213A1 (en) * 2012-09-18 2014-03-27 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
AR097791A1 (es) * 2013-09-27 2016-04-13 Genentech Inc Formulaciones de anticuerpos anti-pdl1
WO2015088847A1 (en) * 2013-12-11 2015-06-18 Glaxosmithkline Llc Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
CN104740609A (zh) * 2013-12-31 2015-07-01 上海中信国健药业股份有限公司 一种受体抗体融合蛋白的药物组合物
CN118286440A (zh) * 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
CN106999561A (zh) * 2014-07-18 2017-08-01 阿德瓦希斯股份有限公司 用于治疗前列腺癌的pd‑1拮抗剂和基于李斯特菌的疫苗的组合
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
TW201705955A (zh) 2015-05-14 2017-02-16 輝瑞大藥廠 包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑及抗－ｐｄ１／抗－ｐｄ－ｌ１抗體之組合療法
WO2016200835A1 (en) * 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
CA2989586A1 (en) 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
PE20181400A1 (es) * 2015-12-07 2018-09-07 Merck Patent Gmbh Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents

Also Published As

Publication number Publication date
AU2018229724A1 (en) 2019-10-31
BR112019018401A2 (pt) 2020-04-07
NZ756413A (en) 2023-08-25
JP7379159B2 (ja) 2023-11-14
KR20190125363A (ko) 2019-11-06
WO2018162446A1 (en) 2018-09-13
CN110392578B (zh) 2024-07-02
TW201834639A (zh) 2018-10-01
CA3055402A1 (en) 2018-09-13
JP2020509065A (ja) 2020-03-26
SG11201908091QA (en) 2019-10-30
US20200016267A1 (en) 2020-01-16
AR111229A1 (es) 2019-06-19
CN110392578A (zh) 2019-10-29
IL268943B2 (en) 2023-06-01
EP3592382A1 (en) 2020-01-15
EA201992027A1 (ru) 2020-02-25
IL268943A (en) 2019-10-31

Similar Documents

Publication Publication Date Title
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
MX2019010367A (es) Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
MY191581A (en) Anti-pd-1 antibodies
WO2016149710A8 (en) Hiv-1 neutralizing antibodies and uses thereof
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
EP3359193A4 (en) Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX2021004774A (es) Formulacion de anticuerpos.
IN2014MU01248A (es)
TR201901228T4 (tr) Vortioksetin piroglutamat.
IN2014CH00840A (es)
EA201791716A1 (ru) Фармацевтический состав
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
BR112016029935A2 (pt) ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
EA201991993A1 (ru) Применение фенилкреатина в качестве ноотропного агента